SHORT MINI-FUTURE - MODERNA | Delayed Deutsche Boerse AG 04:35:14 2024-07-16 am EDT | ||
| 7.66 EUR | -1.54% |
|
| Current month | -4.07% | ||
| 1 month | +25.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 7.66 | -1.54% |
| 24-07-15 | 7.78 | +1.97% |
| 24-07-12 | 7.63 | +0.93% |
| 24-07-11 | 7.56 | -4.91% |
| 24-07-10 | 7.95 | -3.40% |
Delayed Quote Deutsche Boerse AG
Last update July 16, 2024 at 04:35 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VU2UX5 |
| ISIN | DE000VU2UX53 |
| Date issued | 2023-01-30 |
| Strike | 205.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.96 € |
|---|---|
| Lowest since issue | 1.92 € |
| Spread | 0.03 € |
| Spread % | 0.39% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.5
USD
Average target price
145.9
USD
Spread / Average Target
+20.10%
- Stock Market
- Certificates
- Certificat
